Chang Emmanuel, McClellan Andrew J, Farley William J, Li De-Quan, Pflugfelder Stephen C, De Paiva Cintia S
Ocular Surface Center, Department of Ophthalmology, Cullen Eye Institute, Baylor College of Medicine, Houston, Texas, USA.
J Clin Exp Ophthalmol. 2011 Nov 1;2(11). doi: 10.4172/2155-9570.1000191. Epub 2011 Nov 6.
Continuous drug delivery to the ocular surface remains difficult due to the rapid tear clearance of topically applied agents. The purpose of this study was to evaluate biodegradable and biocompatible drug delivery systems on the ocular surface using poly-lactic-co-glycolic acid (PLGA) based polymers.
Fluorescein-labeled albumin and doxycycline were individually encapsulated into a PLGA-based matrix using a water-oil-water double emulsion method. The drug elution rates for various microspheres were evaluated spectrofluorometrically. Particle size was measured using image analysis software. Subconjunctival injections of PLGA microspheres were used to evaluate safety and inflammatory response to the polymer in the murine model. Efficacy of the drug delivery system was evaluated by a single subconjunctival injection of PLGA-doxycycline (a broad metalloproteinase inhibitor) prior to induction of desiccating stress (DS) model in C57BL/6 mice for 5 days.
PLGA-based microspheres successfully elute encapsulated drugs of interest continuously over controlled periods of time. Mean PLGA-based microparticle diameter was 4.6 μm±1.54 μm. Drug elution rates and delivery times were easily modifiable by altering polymers and synthesis parameters. studies demonstrate successful continuous elution of encapsulated drugs for at least 2 weeks. testing of PLGA-doxycycline was efficacious in preventing DS-induced corneal barrier disruption with desiccating stress, similarly to topically applied doxycycline.
PLGA-based drug delivery systems are safe and non-inflammatory. They can be successfully used to treat ocular surface and corneal diseases by continuously delivering biopharmaceuticals of interest.
由于局部应用药物在泪液中清除迅速,向眼表持续给药仍然困难。本研究的目的是使用基于聚乳酸-乙醇酸共聚物(PLGA)的聚合物评估眼表的可生物降解和生物相容性给药系统。
采用水-油-水双乳化法将荧光素标记的白蛋白和多西环素分别包封于基于PLGA的基质中。用荧光分光光度法评估各种微球的药物洗脱率。使用图像分析软件测量粒径。在小鼠模型中,通过结膜下注射PLGA微球来评估对该聚合物的安全性和炎症反应。在C57BL/6小鼠诱导干燥应激(DS)模型前5天,通过单次结膜下注射PLGA-多西环素(一种广泛的金属蛋白酶抑制剂)评估给药系统的疗效。
基于PLGA的微球在可控时间段内成功持续洗脱所包封的目标药物。基于PLGA的微粒平均直径为4.6μm±1.54μm。通过改变聚合物和合成参数可轻松改变药物洗脱率和给药时间。研究表明包封药物成功持续洗脱至少2周。PLGA-多西环素的测试在预防干燥应激导致的DS诱导的角膜屏障破坏方面有效,与局部应用多西环素相似。
基于PLGA的给药系统安全且无炎症。它们可通过持续递送目标生物药物成功用于治疗眼表和角膜疾病。